We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+41.78%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$642M
AUM Growth
+$187M
(+41%)
Cap. Flow
+$68M
Cap. Flow
% of AUM
10.59%
Top 10 Holdings %
Top 10 Hldgs %
58.84%
Holding
55
New
3
Increased
31
Reduced
11
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$20M |
| 2 |
Omnicell
OMCL
|
+$15.4M |
| 3 |
Heron Therapeutics
HRTX
|
+$11.6M |
| 4 |
ARRY
Array Biopharma Inc
ARRY
|
+$11.4M |
| 5 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$8.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$34.8M |
| 2 |
Xencor
XNCR
|
+$4.68M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$4.19M |
| 4 |
Globus Medical
GMED
|
+$3.89M |
| 5 |
HealthStream
HSTM
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.94% |
| 2 | Communication Services | 3.88% |
| 3 | Energy | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$1.96B
| $67.7M | 10.54% |
5,162,063
+401,731
| +8% | +$4.42M |
|
|
2
Tandem Diabetes Care
TNDM
$1.34B
| $41.9M | 6.53% |
1,904,260
-2,829,978
| -60% | -$34.8M |
|
|
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
| $40.1M | 6.25% |
2,391,575
+716,427
| +43% | +$11.4M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $38.8M | 6.04% |
229,721
+49,745
| +28% | +$8.02M |
|
5
AtriCure
ATRC
$1.92B
| $37.3M | 5.81% |
1,380,405
+212,733
| +18% | +$5M |
|
|
6
Omnicell
OMCL
$1.61B
| $34.9M | 5.44% |
666,109
+327,996
| +97% | +$15.4M |
|
|
7
Heron Therapeutics
HRTX
$93.9M
| $32.5M | 5.06% |
836,737
+363,462
| +77% | +$11.6M |
|
8
Harvard Bioscience
HBIO
$27.5M
| $31.8M | 4.96% |
595,101
+50,972
| +9% | +$2.61M |
|
|
IMMU
9
DELISTED
Immunomedics Inc
IMMU
| $27.4M | 4.27% |
1,157,498
+137,578
| +13% | +$2.77M |
|
10
Ligand Pharmaceuticals
LGND
$5.76B
| $25.4M | 3.95% |
196,308
+9,065
| +5% | +$1.01M |
|
|
MODN
11
DELISTED
MODEL N, INC.
MODN
| $24.9M | 3.88% |
1,339,922
+269,899
| +25% | +$4.76M |
|
|
12
Xencor
XNCR
$1.5B
| $20.8M | 3.24% |
561,807
-135,949
| -19% | -$4.68M |
|
|
13
Ionis Pharmaceuticals
IONS
$8.6B
| $20.6M | 3.21% |
494,347
+451,883
| +1,064% | +$20M |
|
14
Nektar Therapeutics
NKTR
$2.39B
| $18.3M | 2.85% |
24,950
+4,944
| +25% | +$5.7M |
|
|
OXFD
15
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $16M | 2.49% |
1,240,391
+613,806
| +98% | +$8.29M |
|
|
CSII
16
DELISTED
Cardiovascular Systems, Inc.
CSII
| $15.8M | 2.45% |
487,207
+17,520
| +4% | +$482K |
|
17
Halozyme
HALO
$9.79B
| $15M | 2.34% |
889,729
+386,700
| +77% | +$7.31M |
|
18
Codexis
CDXS
$151M
| $12.1M | 1.89% |
841,419
+207,754
| +33% | +$2.71M |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $9.28M | 1.44% |
116,224
-50,520
| -30% | -$4.19M |
|
|
XENT
20
DELISTED
Intersect ENT, Inc
XENT
| $8.53M | 1.33% |
227,883
+38,652
| +20% | +$1.52M |
|
|
DVAX
21
DELISTED
Dynavax Technologies
DVAX
| $8.37M | 1.3% |
548,777
+95,143
| +21% | +$1.64M |
|
22
Veracyte
VCYT
$3.7B
| $8.24M | 1.28% |
881,983
+32,417
| +4% | +$228K |
|
|
NVTR
23
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $7.87M | 1.23% |
383,245
-30,401
| -7% | -$513K |
|
|
KTWO
24
DELISTED
K2M Group Holdings, Inc
KTWO
| $6.57M | 1.02% |
292,143
+17,075
| +6% | +$360K |
|
25
Bio-Techne
TECH
$11.2B
| $6.08M | 0.95% |
164,356
+9,736
| +6% | +$372K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2018 Portfolio in Review
As of Q2 2018, First Light Asset Management held 55 positions worth $642M, up 41% from $455M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
First Light Asset Management deployed $68M of net new capital in Q2 2018, opening 3 new positions and adding to 31 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 155,348 shares worth $2.21M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 85% a quarter earlier, followed by Communication Services and Energy.
On the sell side, the largest reduction was Tandem Diabetes Care, an estimated $34.8M trimmed.
- First Light Asset Management's largest Q2 2018 buy was SANGAMO THERAPEUTICS INC: 155,348 shares worth $2.21M.
- First Light Asset Management added most to Ionis Pharmaceuticals in Q2 2018, an estimated $20M increase.
- First Light Asset Management's biggest Q2 2018 reduction was Tandem Diabetes Care, cutting an estimated $34.8M.
- First Light Asset Management's ten largest holdings make up 59% of its $642M portfolio in Q2 2018.
- First Light Asset Management opened 3 new positions and closed 0 in Q2 2018.
- First Light Asset Management's portfolio value rose 41% quarter-over-quarter to $642M.
Based on First Light Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.